• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session

    12/19/22 1:38:15 PM ET
    $ACLX
    $AGFY
    $AKRO
    $ALT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Farming/Seeds/Milling
    Consumer Staples
    Get the next $ACLX alert in real time by email

    Gainers

    • Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial.
    • Axcella Health Inc. (NASDAQ:AXLA) shares rose 153% to $0.4105. Axcella Health shares dipped 63% on Friday after SVB Leerink downgraded the stock from Outperform to Market Perform and lowered its price target from $6 to $2.
    • Camber Energy, Inc. (NYSE:CEI) shares climbed 103% to $0.1257 after the company announced an anticipated effective date of December 21, 2022 for its previously-announced 1-for-50 reverse stock split.
    • Qumu Corporation (NASDAQ:QUMU) gained 98.2% to $0.8722 after Enghouse Systems announced it will acquire the company for $0.90 per share in cash.
    • AirNet Technology Inc. (NASDAQ:ANTE) jumped 64% to $1.93.
    • Viking Therapeutics, Inc. (NASDAQ:VKTX) shares climbed 61% to $6.48 in sympathy with Madrigal Pharmaceuticals which announced a successful trial for liver fibrosis.
    • Nogin, Inc. (NASDAQ:NOGN) rose 44% to $0.72 after declining 39% on Friday. Nogin’s Co-CEO and President Jonathan Huberman recently acquired a total of 19,300 shares at an average price of $0.90.
    • Soleno Therapeutics, Inc. (NASDAQ:SLNO) surged 39% to $1.26 after the company announced a financing commitment for up to $60 million.
    • Terns Pharmaceuticals, Inc. (NASDAQ:TERN) rose 39% to $9.55 in sympathy with Madrigal Pharmaceuticals, which gained after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial.
    • Caravelle International Group (NASDAQ:CACO) gained 38.8% to $5.83.
    • Agrify Corporation (NASDAQ:AGFY) climbed 38% to $0.3410 after dipping around 70% on Friday. Agrify announced pricing of a public offering.
    • Innate Pharma S.A. (NASDAQ:IPHA) rose 37% to $2.6032 after the company and Sanofi announced an expansion of their collaboration for natural killer cell therapeutics in oncology. Innate will receive a €25 million upfront payment.
    • Greenidge Generation Holdings Inc. (NASDAQ:GREE) rose 30.3% to $0.3260 after dropping 39% on Friday.
    • Cazoo Group Ltd (NYSE:CZOO) rose 24.4% to $0.1618. Cazoo recently sold its Spanish subscription business, Swipcar, to Renting Finders S.L.
    • Otonomy, Inc. (NASDAQ:OTIC) rose 24.1% to $0.1118 after dropping over 21% on Friday.
    • Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) gained 24% to $31.53 after the company said its Emraclidine Ambulatory Blood Pressuring Monitoring Trial did not cause an increase in blood pressure.
    • Aspen Group, Inc. (NASDAQ:ASPU) gained 23.3% to $0.2833. Aspen Group recently reported better-than-expected Q2 sales results.
    • iHuman Inc. (NYSE:IH) gained 21.2% to $2.80.
    • Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) gained 20.3% to $2.84.
    • Future FinTech Group Inc. (NASDAQ:FTFT) jumped 19.1% to $0.5480.
    • Celcuity Inc. (NASDAQ:CELC) gained 19% to $11.91.
    • AppHarvest, Inc. (NASDAQ:APPH) rose 18.7% to $0.5563.
    • Troika Media Group, Inc. (NASDAQ:TRKA) rose 17.8% to $0.1178 after dropping around 6% on Friday.
    • Bird Global, Inc. (NYSE:BRDS) gained 17.7% to $0.1765.
    • Professional Diversity Network, Inc. (NASDAQ:IPDN) surged 17.6% to $0.7771.
    • Argo Blockchain plc (NASDAQ:ARBK) rose 17.5% to $0.45 after declining 21% on Friday.
    • Horizon Global Corporation (NYSE:HZN) gained 16.7% to $0.70.
    • PainReform Ltd. (NASDAQ:PRFX) gained 14% to $0.57.
    • Akili, Inc. (NASDAQ:AKLI) shares rose 14% to $1.14 after dipping 35% on Friday.
    • CI&T Inc (NYSE:CINT) gained 12.8% to $5.89. CI&T said that it has become an Amazon Web Services (AWS) Advanced Tier Services Partner within the AWS Partner Network.
    • Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) rose 11.6% to $1.15 after dropping 36% on Friday.
    • Reading International, Inc. (NASDAQ:RDIB) gained 10.2% to $19.77.
    • 17 Education & Technology Group Inc. (NASDAQ:YQ) rose 10.2% to $1.8286 after jumping 29% on Friday. 17 Education & Technology recently posted a Q3 loss of $0.01 per share.
    • Summit Therapeutics Inc. (NASDAQ:SMMT) gained 10% to $3.9699.
    • Perfect Corp. (NYSE:PERF) gained 8.4% to $7.10.
    • ObsEva SA (NASDAQ:OBSV) rose 6.6% to $0.1472. The company reported dismissal of moratorium proceedings.


    Losers

    • Cosmos Health Inc. (NASDAQ:COSM) shares dipped 59.6% to $9.30 after the company reported pricing of $32.5 million registered direct offering and concurrent private placement priced at-the-market.
    • Forward Pharma A/S (NASDAQ:FWP) fell 38.7% to $1.60. Forward Pharma announced expected delisting of its American Depositary Shares from the Nasdaq Capital Market.
    • Scopus BioPharma Inc. (NASDAQ:SCPS) fell 34.7% to $0.0556.
    • NantHealth, Inc. (NASDAQ:NH) fell 30.7% to $3.95. NantHealth recently announced a 1-for-15 reverse stock split.
    • ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) dropped 25.1% to $2.4109.
    • VistaGen Therapeutics, Inc. (NASDAQ:VTGN) declined 25% to $0.1092. VistaGen Therapeutics recently announced the FDA granted Fast Track designation for the development of PH10 for the treatment of major depressive disorder.
    • Invacare Corporation (NYSE:IVC) dropped 25% to $0.4499.
    • Healthcare Triangle, Inc. (NASDAQ:HCTI) fell 23.7% to $0.2364.
    • Lanvin Group Holdings Limited (NYSE:LANV) fell 23% to $7.70 after surging 31% on Friday.
    • Neptune Wellness Solutions Inc. (NASDAQ:NEPT) dropped 22.8% to $0.27. Neptune Wellness Solutions reported a net loss of $37.3 million for the fiscal second quarter 2023 versus a year-ago net loss of $12.1 million. Its net sales revenue declined to $12 million from $12.5 million.
    • PLDT Inc. (NYSE:PHI) dropped 22.4% to $20.81.
    • BiomX Inc. (NYSE:PHGE) shares fell 22.1% to $0.1720 after jumping 63% on Friday. BiomX, last month, posted a Q3 loss of $0.23 per share.
    • Tellurian Inc. (NASDAQ:TELL) dropped 20.3% to $1.93.
    • Gossamer Bio, Inc. (NASDAQ:GOSS) declined 20.3% to $2.1750.
    • Akero Therapeutics, Inc. (NASDAQ:AKRO) fell 18.9% to $38.10.
    • Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) fell 18.8% to $12.45. STAT News reporter Adam Feuerstein tweets "Intercept Pharmaceuticals Down 10% Because OCA's Future In NASH Looks Bleaker. Investors Really Want Intercept To Ditch NASH And Focus On The Approved PBC Indication."
    • TMC the metals company Inc. (NASDAQ:TMC) dropped 17.9% to $0.5598.
    • Meihua International Medical Technologies Co., Ltd. (NASDAQ:MHUA) fell 17.8% to $9.28.
    • Nexa Resources S.A. (NYSE:NEXA) dropped 17.8% to $5.51.
    • Altimmune, Inc. (NASDAQ:ALT) fell 17.2% to $9.51.
    • 89bio, Inc. (NASDAQ:ETNB) fell 16.8% to $8.78.
    • Vivani Medical, Inc. (NASDAQ:VANI) dropped 16.7% to $0.8578.
    • Minim, Inc. (NASDAQ:MINM) fell 16.5% to $0.1773 after jumping 22% on Friday.
    • Carvana Co. (NYSE:CVNA) dropped 15.7% to $4.24.
    • Synaptogenix, Inc. (NASDAQ:SNPX) fell 14.3% to $1.0228. Synaptogenix shares dropped 75% on Friday after the company announced results from its Phase 2 clinical trial of Bryostatin-1 for the treatment of advanced Alzheimer's disease, in which the primary endpoint was not met with statistical significance.
    • Cue Health Inc. (NASDAQ:HLTH) fell 14.2% to $2.5050.
    • C4 Therapeutics, Inc. (NASDAQ:CCCC) dropped 14.1% to $6.32.
    • Seer, Inc. (NASDAQ:SEER) declined 13.6% to $5.40.
    • New Pacific Metals Corp. (NYSE:NEWP) fell 13.4% to $2.50.
    • Mondee Holdings, Inc. (NASDAQ:MOND) dropped 13.4% to $10.61.
    • Arcellx, Inc. (NASDAQ:ACLX) fell 12.2% to $27.97.
    • Richardson Electronics, Ltd. (NASDAQ:RELL) dropped 11.6% to $21.66.
    • Gevo, Inc. (NASDAQ:GEVO) fell 10.7% to $1.7950.
    • Cinemark Holdings, Inc. (NYSE:CNK) fell 10.5% to $9.69.
    • Domo, Inc. (NASDAQ:DOMO) dropped 10.5% to $14.81. Morgan Stanley maintained Domo with an Overweight and lowered the price target from $51 to $24.
    • Mersana Therapeutics, Inc. (NASDAQ:MRSN) dipped 10.5% to $5.82.
    • ChargePoint Holdings, Inc. (NYSE:CHPT) declined 9.6% to $9.45.
    • MasterBrand, Inc. (NYSE:MBC) fell 9.5% to $8.42 after jumping over 20% on Friday.
    • Relay Therapeutics, Inc. (NASDAQ:RLAY) dropped 9.4% to $15.44.
    • Melco Resorts & Entertainment Limited (NASDAQ:MLCO) fell 9.3% to $10.90.
    • AMC Entertainment Holdings, Inc. (NYSE:AMC) dropped 8.3% to $4.8650. AMC Entertainment announced Monday that it has raised $162 million from its AMC Preferred Equity Units since launching the stock just a few months ago.
    • Ardelyx, Inc (NASDAQ:ARDX) fell 7.9% to $1.8050 after the company provided an update regarding the appeal to the Complete Response Letter for the New Drug Application for XPHOZAH.
    • Mullen Automotive, Inc. (NASDAQ:MULN) fell 7.8% to $0.2787. Mullen Automotive recently announced it received a purchase order from Randy Marion Automotive Group for 6,000 Class 1 EV cargo vans.

    Also check this out Over $13 Million Bet On This Biotechnology Stock? Check Out These 4 Stocks Insiders Are Buying.

    Get the next $ACLX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACLX
    $AGFY
    $AKRO
    $ALT

    CompanyDatePrice TargetRatingAnalyst
    Carvana Co.
    $CVNA
    4/6/2026$360.00Buy → Neutral
    BofA Securities
    Viking Therapeutics Inc.
    $VKTX
    3/26/2026Peer Perform
    Wolfe Research
    Terns Pharmaceuticals Inc.
    $TERN
    3/25/2026Buy → Neutral
    H.C. Wainwright
    Gossamer Bio Inc.
    $GOSS
    3/23/2026Overweight → Neutral
    Cantor Fitzgerald
    Altimmune Inc.
    $ALT
    3/18/2026$12.00Buy
    Truist
    Summit Therapeutics Inc.
    $SMMT
    3/16/2026$15.00Buy → Hold
    Jefferies
    Innate Pharma S.A. ADS
    $IPHA
    3/12/2026$8.00Buy
    BTIG Research
    Gossamer Bio Inc.
    $GOSS
    2/24/2026$1.00Outperform → Neutral
    Wedbush
    More analyst ratings

    $ACLX
    $AGFY
    $AKRO
    $ALT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Weaver Gregory L bought $17,700 worth of shares (5,000 units at $3.54), increasing direct ownership by 22% to 28,078 units (SEC Form 4)

    4 - Altimmune, Inc. (0001326190) (Issuer)

    3/9/26 7:05:04 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Durso Jerome Benedict bought $70,790 worth of shares (20,000 units at $3.54), increasing direct ownership by 160% to 32,500 units (SEC Form 4)

    4 - Altimmune, Inc. (0001326190) (Issuer)

    3/9/26 7:00:05 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Mott David M bought $1,946,331 worth of shares (333,333 units at $5.84), increasing direct ownership by 11% to 3,302,918 units (SEC Form 4)

    4 - ARDELYX, INC. (0001437402) (Issuer)

    2/23/26 9:01:11 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACLX
    $AGFY
    $AKRO
    $ALT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Carvana downgraded by BofA Securities with a new price target

    BofA Securities downgraded Carvana from Buy to Neutral and set a new price target of $360.00

    4/6/26 8:41:44 AM ET
    $CVNA
    Retail-Auto Dealers and Gas Stations
    Consumer Discretionary

    Wolfe Research initiated coverage on Viking Therapeutics

    Wolfe Research initiated coverage of Viking Therapeutics with a rating of Peer Perform

    3/26/26 9:00:52 AM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Terns Pharmaceuticals downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Terns Pharmaceuticals from Buy to Neutral

    3/25/26 10:23:07 AM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACLX
    $AGFY
    $AKRO
    $ALT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

    CONSHOHOCKEN, Pa., April 07, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on April 1, 2026 to 20 new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 Inducement Plan. The equity awards were approved by Madrigal's independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4). The equity awards were granted as an inducement material to employees' acceptance of employment with the company. The new employees received, in the aggregate

    4/7/26 4:05:00 PM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc.

    Merck (NYSE:MRK), known as MSD outside of the United States and Canada, is commencing today, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Terns Pharmaceuticals, Inc. ("Terns") (NASDAQ:TERN). On March 25, 2026, Merck announced that it had entered into a definitive agreement to acquire Terns. Upon the successful closing of the tender offer, stockholders of Terns will receive $53.00 net in cash for each share of Terns common stock validly tendered and not validly withdrawn in the offer, without interest and less any applicable tax withholding. Following the purchase of shares in the tender offer, Terns will become a wholly owned subsidiary o

    4/7/26 9:00:00 AM ET
    $MRK
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TalentAlly, a Subsidiary of Professional Diversity Network, Inc., Launches Next-Generation Career Fair Hiring Platform Powered by ByteCompute.ai

    CHICAGO, April 06, 2026 (GLOBE NEWSWIRE) -- Professional Diversity Network, Inc. (NASDAQ:IPDN) ("IPDN" or the "Company") today announced that its subsidiary, TalentAlly, has launched a next-generation platform, a comprehensive virtual hiring solution powered by ByteCompute.ai. The platform is designed to deliver measurable improvements in candidate engagement, recruiter efficiency, and hiring outcomes across virtual, in-person, and hybrid career events. With more than 12 years of experience in career fairs and recruitment solutions, the Company has supported over 1,300 employers and facilitated connections for more than half a million candidates. The launch of the platform represents the

    4/6/26 9:00:00 AM ET
    $IPDN
    Computer Software: Programming Data Processing
    Technology

    $ACLX
    $AGFY
    $AKRO
    $ALT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Gierhart Wanda Marie

    4 - Cinemark Holdings, Inc. (0001385280) (Issuer)

    4/7/26 5:16:08 PM ET
    $CNK
    Movies/Entertainment
    Consumer Discretionary

    SEC Form 4 filed by Gamble Sean

    4 - Cinemark Holdings, Inc. (0001385280) (Issuer)

    4/7/26 4:52:40 PM ET
    $CNK
    Movies/Entertainment
    Consumer Discretionary

    SEC Form 4 filed by Gill John

    4 - Altimmune, Inc. (0001326190) (Issuer)

    4/6/26 4:05:16 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACLX
    $AGFY
    $AKRO
    $ALT
    SEC Filings

    View All

    Amendment: Healthcare Triangle Inc. filed SEC Form 8-K: Financial Statements and Exhibits, Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Regulation FD Disclosure

    8-K/A - Healthcare Triangle, Inc. (0001839285) (Filer)

    4/7/26 5:05:03 PM ET
    $HCTI
    EDP Services
    Technology

    SEC Form SC 14D9 filed by Terns Pharmaceuticals Inc.

    SC 14D9 - Terns Pharmaceuticals, Inc. (0001831363) (Subject)

    4/7/26 7:44:29 AM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC TO-T filed by Terns Pharmaceuticals Inc.

    SC TO-T - Terns Pharmaceuticals, Inc. (0001831363) (Subject)

    4/7/26 7:00:59 AM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACLX
    $AGFY
    $AKRO
    $ALT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for REZDIFFRA issued to MADRIGAL PHARMACEUTICALS INC

    Submission status for MADRIGAL PHARMACEUTICALS INC's drug REZDIFFRA (ORIG-1) with active ingredient RESMETIROM has changed to 'Approval' on 03/14/2024. Application Category: NDA, Application Number: 217785, Application Classification: Type 1 - New Molecular Entity

    3/14/24 3:35:50 PM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for XPHOZAH issued to ARDELYX INC

    Submission status for ARDELYX INC's drug XPHOZAH (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated

    10/20/23 4:37:52 AM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for XPHOZAH issued to ARDELYX INC

    Submission status for ARDELYX INC's drug XPHOZAH (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Labeling

    10/18/23 4:43:04 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACLX
    $AGFY
    $AKRO
    $ALT
    Leadership Updates

    Live Leadership Updates

    View All

    TalentAlly, a Subsidiary of Professional Diversity Network, Inc., Launches Next-Generation Career Fair Hiring Platform Powered by ByteCompute.ai

    CHICAGO, April 06, 2026 (GLOBE NEWSWIRE) -- Professional Diversity Network, Inc. (NASDAQ:IPDN) ("IPDN" or the "Company") today announced that its subsidiary, TalentAlly, has launched a next-generation platform, a comprehensive virtual hiring solution powered by ByteCompute.ai. The platform is designed to deliver measurable improvements in candidate engagement, recruiter efficiency, and hiring outcomes across virtual, in-person, and hybrid career events. With more than 12 years of experience in career fairs and recruitment solutions, the Company has supported over 1,300 employers and facilitated connections for more than half a million candidates. The launch of the platform represents the

    4/6/26 9:00:00 AM ET
    $IPDN
    Computer Software: Programming Data Processing
    Technology

    Gevo Appoints Key Executive Team Members

    ENGLEWOOD, Colo., April 01, 2026 (GLOBE NEWSWIRE) -- Gevo, Inc. (NASDAQ:GEVO), a leader in renewable fuels, chemicals, and carbon management, today announced the appointments of Kyle James as Chief Commercial Officer and Dave Kettner as General Counsel, further supporting Gevo's broader leadership transition. The executive additions round out newly appointed Chief Executive Officer Paul Bloom's executive team, increasing expertise across renewable fuels, chemicals and value-driven commercial strategies and expanding the company's legal expertise and first-hand experience scaling renewable fuels and technology businesses. "I am excited to welcome Kyle and Dave to Gevo. Kyle's deep experien

    4/1/26 9:00:00 AM ET
    $GEVO
    Major Chemicals
    Industrials

    Rajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx

    WALTHAM, Mass., April 01, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced the appointment of Rajani Dinavahi, MD, as Chief Medical Officer (CMO). Dr. Dinavahi brings more than two decades of experience in healthcare and biotechnology, spanning multiple therapeutic areas and modalities. She has extensive experience across immuno-oncology, autoimmune diseases, metabolic disease, nephrology and transplantation, with a track record of advancing programs from early development through Phase 3 and regulatory approval. Dr. Dinavahi m

    4/1/26 8:01:00 AM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACLX
    $AGFY
    $AKRO
    $ALT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Carvana Co.

    SC 13D/A - CARVANA CO. (0001690820) (Subject)

    12/16/24 6:13:26 PM ET
    $CVNA
    Retail-Auto Dealers and Gas Stations
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by Agrify Corporation

    SC 13D/A - Agrify Corp (0001800637) (Subject)

    11/29/24 4:30:03 PM ET
    $AGFY
    Farming/Seeds/Milling
    Consumer Staples

    Amendment: SEC Form SC 13D/A filed by Agrify Corporation

    SC 13D/A - Agrify Corp (0001800637) (Subject)

    11/29/24 4:30:03 PM ET
    $AGFY
    Farming/Seeds/Milling
    Consumer Staples

    $ACLX
    $AGFY
    $AKRO
    $ALT
    Financials

    Live finance-specific insights

    View All

    Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio

    VYKAT™ XR (diazoxide choline) is the First and Only FDA Approved Treatment for Hyperphagia in Prader-Willi Syndrome and Represents a Transformative Therapy Expands Neurocrine's High-Growth Commercial Portfolio to Three First-in-Class Medicines Including INGREZZA® (valbenazine) and CRENESSITY® (crinecerfont)Establishes a Durable Platform for Long-Term Revenue Growth and Value Creation, Supported by Strong VYKAT XR Intellectual Property Estate Expected to Extend into the mid-2040sNeurocrine to Host Conference Call at 8:00 AM ET Today to Discuss Transaction SAN DIEGO and REDWOOD CITY, Calif., April 6, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) and Soleno Therapeutics, Inc.

    4/6/26 7:00:00 AM ET
    $NBIX
    $SLNO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus

    Richardson Electronics Announces Date of Third Quarter Fiscal Year 2026 Conference Call

    LAFOX, Ill., April 01, 2026 (GLOBE NEWSWIRE) -- Richardson Electronics, Ltd. (NASDAQ:RELL) plans to release its financial results for its third quarter ended February 28, 2026 after the close of business on Wednesday, April 8, 2026. The release will be distributed by GlobeNewswire and will be available on the Company's website at www.rell.com. On Thursday, April 9, 2026, at 9:00 a.m. Central Time, Edward J. Richardson, Chairman and Chief Executive Officer, and Robert J. Ben, Chief Financial Officer, will host a conference call to discuss the Company's third quarter fiscal year 2026 results. A question-and-answer session will be included as part of the call's agenda. Participant Instructi

    4/1/26 4:15:00 PM ET
    $RELL
    Electronic Components
    Technology

    Carvana to Report First Quarter 2026 Results and Host Quarterly Conference Call on April 29

    Carvana (NYSE:CVNA), the industry pioneer for buying and selling cars online, today announced it will report its first quarter 2026 financial results for the period ended March 31, 2026, after the market closes on Wednesday, April 29, 2026. On that day, management will hold a conference call and webcast at 5:30 p.m. ET (2:30 p.m. PT) to review and discuss the company's business and results. What:   Carvana First Quarter 2026 Financial Results Conference Call When:   Wednesday, April 29, 2026 Time:   5:30 p.m. ET (2:30 p.m. PT) Live Call:   (833) 255-2830 or (412) 902-6715 An archived webcast of the conference call will be accessible

    4/1/26 9:00:00 AM ET
    $CVNA
    Retail-Auto Dealers and Gas Stations
    Consumer Discretionary

    $ACLX
    $AGFY
    $AKRO
    $ALT
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Insider Analysis: Purchase at Gossamer Bio Inc. on Jun 21

    Gossamer Bio Inc. recently witnessed an insider purchase by COO/CFO Bryan Giraudo, who acquired $59,110 worth of shares consisting of 100,000 units at $0.59 per share. Insider purchases like this can provide valuable insights for investors, indicating confidence from individuals within the company about its future prospects. Examining previous insider transactions, on 2024-03-19, insiders Peterson Caryn and Aranda Richard each sold $5,343 worth of shares at $1.33, leading to a decrease in their direct ownership percentages. Similarly, on 2024-03-28, Hasnain Faheem, Giraudo Bryan, and Christian Waage sold shares worth $26,773, $7,431, and $7,430, respectively, impacting their direct ownershi

    6/21/24 3:17:31 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care